Research programme: Flavivirus infections therapeutics- Protinhi Therapeutics
Alternative Names: Pan-Flavi - Protinhi TherapeuticsLatest Information Update: 28 Jun 2024
At a glance
- Originator Protinhi Therapeutics
- Class Antivirals; Small molecules
- Mechanism of Action Viral protease inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Dengue
- Research West Nile virus infections; Zika virus infection
- No development reported Flavivirus infections
Most Recent Events
- 28 Jun 2024 No recent reports of development identified for research development in Flavivirus-infections in Netherlands (PO)
- 12 Jun 2023 Research programme: viral protease inhibitors - Protinhi Therapeutics is available for licensing as of 12 June 2023. https://www.protinhi.com/rd/
- 30 Nov 2021 Preclinical trials in Dengue in Netherlands (PO) (Protinhi Therapeutics pipeline, November 2021)